DOES TRANSRECTAL ULTRASONOGRAPHY-GUIDED BIOPSY OF THE PROSTATE LEAD TO POSSIBLE FURTHER METASTASIS VIA CIRCULATING TUMOR CELLS?
BACKGROUND/AIM We evaluated that whether TRUS-guided prostate biopsy might lead to spillage of tumor cells into peripheral blood as a result of disruption of the epithelial barrier and ultimately result in metastasis. MATERIALS AND METHODS Eighty-eight patients underwent TRUS-guided prostate needle biopsy (TRNB) due to prostate-specific antigen(PSA) increase, or abnormal digital rectal examination at the Samsun Research and Training Hospital, Samsun, TURKEY between April 2016 and September 2018. Approximately 10 ml of whole blood was collected from patients before, and one week and one month after biopsy. Samples were analyzed for CD117 positivity and prostate-specific membrane antigen (PSMA) levels using flow cytometry. Patients with pathologically determined "prostate cancer" and without CD117 positivity before biopsy were included in the study. RESULTS The study group consisted of 55 patients. Subjects? PSA levels ranged from 2.3 to 40.0 ng/mL (median: 7.9 ng/mL), and their Gleason score was median:7 (range: 5-9). PSMA levels ranged between 9.3 ng/mL and 118.5 ng/mL, and CD117 antigen levels between 0 and 5.We detected no CD117-positive cells in blood samples collected seven days and one month after biopsy. CONCLUSION We detected no CTCs in the peripheral circulation following biopsy. Prostate needle biopsy seems to be a safe method in terms of spillage of tumor cells into blood circulation as a sign of possible further metastasis.